U.S. Markets closed

Gilead Sciences, Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.50-0.06 (-0.09%)
At close: 4:00PM EDT
People also watch
CELGBIIBAMGNBMYREGN
Interactive chart
Previous Close64.56
Open64.37
Bid64.50 x 400
Ask64.59 x 2000
Day's Range64.31 - 64.75
52 Week Range63.88 - 88.85
Volume3,646,119
Avg. Volume7,804,596
Market Cap84.28B
Beta0.99
PE Ratio (TTM)6.82
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (3.22%)
Ex-Dividend Date2017-03-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist9 hours ago

    TAF-Based Regimens Could Boost Gilead Sciences’ Revenue Growth

    Gilead Sciences’ (GILD) tenofovir alafenamide fumarate (or TAF) based regimens have seen high adoption rates in the US and European markets.

  • American City Business Journals10 hours ago

    Gilead Sciences CFO named ‘Financial Woman of the Year’

    The Financial Women of San Francisco selected Gilead Sciences Chief Financial Officer Robin Washington as its 2017 Financial Woman of the Year. Washington was also recognized this week as the recipient of the lifetime achievement award at the “2017 Bay Area CFO of the Year Awards,” a program conducted by Larkin Street Youth Services in partnership with the Business Times. In accepting her award this week, it was clear that Washington spent a good portion of her career staying one step ahead of Oracle’s M&A department.

  • Market Realist11 hours ago

    Genvoya Could Drive Gilead Sciences’ Revenue Growth in 2017

    In 1Q17, Gilead Sciences’ (GILD) Genvoya generated revenues of around $769 million. The drug has seen double-digit sequential sales growth in every quarter since its launch in November 2015.